How to Manage and Monitor Cardiac Dysfunction in Patients With Metastatic HER2-Positive Breast Cancer.

1 Fam-trastuzumab deruxtecan (T-DXd) has recently demonstrated superiority over T-DM1 on the basis of the results of DESTINY-Breast03 (DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 [HER2]-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane), with a significant improvement in PFS (25.1 vs 7.2 months) and a strong trend toward an OS benefit favoring the T-DXd arm, and hence is now considered preferred second-line treatment. 5 In HER2CLIMB (A Study of Tucatinib vs.

also in 5,725 other papers